Indefinite Delivery Contract SPE2DU25D9167

The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications, positioning DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain.

The original solicitation was for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts, which aim to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, the United States Coast Guard, Designated Providers, Other Government Agencies, and the US Naval Fleet. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with the intention to make multiple awards for separate regions on a Lowest Price Technically Acceptable (LPTA) basis. The estimated total value of the PPV-G GEN V contracts is $30.3 billion, covering a 30-month base period and three 30-month option periods.